{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:15:20Z","timestamp":1775229320046,"version":"3.50.1"},"reference-count":30,"publisher":"Central Research Institute for Epidemiology","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["virusjour.crie.ru"],"crossmark-restriction":false},"short-container-title":["Problems of Virology"],"abstract":"<jats:p>Introduction. Herpes simplex virus type 1 (HSV-1) causes various diseases in humans that can lead to disability and death. Current treatments are effective and relatively safe. However, the high prevalence of HSV, the necessity for long-term therapy associated with the development of drug resistance in the virus (mainly in immunocompromised patients) and severe side effects of second-line drugs complicate treatment. Obviously, there is a necessity to develop therapeutic agents with a new mechanism of action and new ways of influencing herpes infection to improve the effectiveness of therapy. The combined use of drugs with different mechanisms of action is one such approach.\r\nThe aim of the study is to evaluate the antiviral activity of combinations of LAS-131 ((3S)-4-[6-(purin-6-yl)aminohexanoyl]-3,4-dihydro-3-methyl-7,8-difluoro-2H-[1,4]-benzoxazine) with basic antiherpetic drugs and with two new compounds.\r\nMaterials and methods. The effect of LAS-131 combinations against HSV-1 was studied by constructing an isobologram and calculating the fractional inhibitory concentration index.\r\nResults. LAS-131 selectively inhibits the reproduction of acyclovir-sensitive and -resistant HSV-1 variants (IC50 is 1.95 \u03bcg\/mL, selectivity index is 63). Its target protein is the large subunit of the terminase complex (pUL15). When LAS-131 is used in combination with viral DNA polymerase inhibitors (acyclovir and related compounds) or with the minor-groove inhibitor 15Lys-bis-netropsin, a potentiating effect is observed, which allows decreasing the concentrations of the combined compounds by 4 times or more while maintaining antiviral activity. LAS-131 interacted additively with foscarnet, ribavirin, and \u03b1-interferon.\r\nConclusion. Combinations of LAS-131 with known antiviral agents have been established, providing synergistic and additive effects of interaction against HSV-1.<\/jats:p>","DOI":"10.36233\/0507-4088-336","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:24:39Z","timestamp":1774286679000},"page":"21-31","update-policy":"https:\/\/doi.org\/10.36233\/0372-9311-crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Antiviral potential of combinations of etiotropic antiherpetic agents including LAS-131, a novel terminase complex inhibitor, to affect the reproduction of herpes simplex virus type 1 (&lt;i&gt;Orthoherpesviridae: Simplexvirus: Simplexvirus humanalpha1&lt;\/i&gt;)"],"prefix":"10.36233","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6162-1650","authenticated-orcid":false,"given":"Georgy A.","family":"Galegov","sequence":"additional","affiliation":[{"name":"The N.F. Gamaleya Research Center of Epidemiology and Microbiology, The Russian Ministry of Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2467-0282","authenticated-orcid":false,"given":"Valeriya L.","family":"Andronova","sequence":"additional","affiliation":[{"name":"The N.F. Gamaleya Research Center of Epidemiology and Microbiology, The Russian Ministry of Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8349-6061","authenticated-orcid":false,"given":"Olga A.","family":"Vozdvizhenskaya","sequence":"additional","affiliation":[{"name":"Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0964-9311","authenticated-orcid":false,"given":"Galina L.","family":"Levit","sequence":"additional","affiliation":[{"name":"Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-358X","authenticated-orcid":false,"given":"Valery N.","family":"Charushin","sequence":"additional","affiliation":[{"name":"Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-6218","authenticated-orcid":false,"given":"Victor P.","family":"Krasnov","sequence":"additional","affiliation":[{"name":"Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22004","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Andronova V.L. Modern ethiotropic chemotherapy of herpesvirus infections: advances, new trends and perspectives. Alphaherpesvirinae (Part I). Voprosy virusologii. 2018; 63(3): 106\u201314. https:\/\/doi.org\/10.18821\/0507-4088-2018-63-3-106-114 https:\/\/elibrary.ru\/uxpwxg (in Russian)","DOI":"10.18821\/0507-4088-2018-63-3-106-114"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Leflore S., Anderson P.L., Fletcher C.V. A risk-benefit evaluation of acyclovir for the treatment and prophylaxis of herpes simplex virus infections. Drug Saf. 2000; 23(2): 131\u201342. https:\/\/doi.org\/10.2165\/00002018-200023020-00004","DOI":"10.2165\/00002018-200023020-00004"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Sauerbrei A., Bohn-Wippert K., Kaspar M., Krumbholz A., Karrasch M., Zell R. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2. J. Antimicrob. Chemother. 2016; 71(1): 6\u201316. https:\/\/doi.org\/10.1093\/jac\/dkv285","DOI":"10.1093\/jac\/dkv285"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Men\u00e9ndez-Arias L., Delgado R. Update and latest advances in antiretroviral therapy. Trends Pharmacol. Sci. 2022; 43(1): 16\u201329. https:\/\/doi.org\/10.1016\/j.tips.2021.10.004","DOI":"10.1016\/j.tips.2021.10.004"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J. Hepatol. 2016; 64(2): 486\u2013504. https:\/\/doi.org\/10.1016\/j.jhep.2015.09.011","DOI":"10.1016\/j.jhep.2015.09.011"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Krasnov V.P., Musiyak V.V., Vozdvizhenskaya O.A., Gruzdev D.A., Chulakov E.N., Vigorov A.Y., et al. N-[\u03c9-(PURIN-6-YL)AMINOALKANOYL] derivatives of chiral heterocyclic amines as promising anti-herpesvirus agents. European Journal of Organic Chemistry. 2019; 2019(30): 4811\u201321. https:\/\/doi.org\/10.1002\/ejoc.201900727 https:\/\/elibrary.ru\/yzrkpz","DOI":"10.1002\/ejoc.201900727"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Krasnov V.P., Andronova V.L., Belyavsky A.V., Borisevich S.S., Galegov G.A., Kandarakov O.F., et al. Large subunit of the human herpes simplex virus terminase as a promising target in design of anti-herpesvirus agents. Molecules. 2023; 28(21): 7375. https:\/\/doi.org\/10.3390\/molecules28217375 https:\/\/elibrary.ru\/pslwsv","DOI":"10.3390\/molecules28217375"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Gus\u2019kova A.A., Skoblov M.Y., Korovina A.N., Yasko M.V., Karpenko I.L., Kukhanova M.K., et al. Antiherpetic properties of acyclovir 5\u2019-hydrogenphosphonate and the mutation analysis of herpes virus resistant strains. Chem. Biol. Drug Des. 2009; 74(4): 382\u20139. https:\/\/doi.org\/10.1111\/j.1747-0285.2009.00874.x","DOI":"10.1111\/j.1747-0285.2009.00874.x"},{"key":"ref9","unstructured":"Galegov G.A., Andronova V.L., Gurskii G.V., Surovaya A.N., Grokhovskii S.L. A dimeric derivative of netropsin-15-lys-bis-netropsin and a detection method based on it, possessing antiherpetic activity. Patent RF \u2116 2265610C1; 2005. (in Russian)"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Guskova A.A., Skoblov M.Yu., Baranova A.V., Yankovsky N.K., Zagurny A.V., Skoblov Yu.S., et al. Molecular genetic analysis of thymidine kinase of the herpes simplex virus type 1. Molecular Biology. 2005; 39(1): 137\u201340. https:\/\/doi.org\/10.1007\/s11008-005-0019-7 https:\/\/elibrary.ru\/ljdvpf","DOI":"10.1007\/s11008-005-0019-7"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Korovina A.N., Kochetkov S.N., Kukhanova M.K., Gus\u2019kova A.A., Skoblov M.Y., Andronova V.L., et al. Mutations in the DNA polymerase and thymidine kinase genes of herpes simplex virus clinical isolates resistant to antiherpetic drugs. Molecular Biology. 2010; 44(3): 431\u201338. https:\/\/doi.org\/10.1134\/S0026893310030118 https:\/\/elibrary.ru\/mxpusl","DOI":"10.1134\/S0026893310030118"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Strober W. Trypan blue exclusion test of cell viability. Curr. Protoc. Immunol. 2015; 111: A3.B.1\u20133. https:\/\/doi.org\/10.1002\/0471142735.ima03bs111","DOI":"10.1002\/0471142735.ima03bs111"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Huang R.Y., Pei L., Liu Q., Chen S., Dou H., Shu G., et al. Isobologram analysis: a comprehensive review of methodology and current research. Front. Pharmacol. 2019; 10: 1222. https:\/\/doi.org\/10.3389\/fphar.2019.01222","DOI":"10.3389\/fphar.2019.01222"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Skoblov Y.S., Karpenko I.L., Jasko M.V., Kukhanova M.K., Andronova V.L., Galegov G.A., et al. Cell metabolism of acyclovir phosphonate derivatives and antiherpesvirus activity of their combinations with alpha2-interferon. Chem. Biol. Drug Des. 2007; 69(6): 429\u201334. https:\/\/doi.org\/10.1111\/j.1747-0285.2007.00517.x","DOI":"10.1111\/j.1747-0285.2007.00517.x"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Surovaya A.N., Grokhovskii S.L., Gurskii Ya.G., Andronova V.L., Arkhipova V.S., Bazhulina N.P., et al. Complex of herpesvirus initiator protein UL9 with DNA as a platform for the creation of novel antiviral drug agents. Biofizika. 2010; 55(2): 239\u201351. (in Russian)","DOI":"10.1134\/S0006350910020077"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Bazhulina N.P., Surovaya A.N., Gursky Y.G., Andronova V.L., Moiseeva E.D., Nikitin C.A., et al. Complex of the herpes simplex virus type 1 origin binding protein UL9 with DNA as a platform for the design of a new type of antiviral drugs. J. Biomol. Struct. Dyn. 2014; 32(9): 1456\u201373. https:\/\/doi.org\/10.1080\/07391102.2013.820110","DOI":"10.1080\/07391102.2013.820110"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Yang Y., Yang P., Wang N., Chen Z., Su D., Zhou Z.H., et al. Architecture of the herpes virus genome-packaging complex and implications for DNA translocation. Protein Cell. 2020; 11(5): 339\u201351. https:\/\/doi.org\/10.1007\/s13238-020-00710","DOI":"10.1007\/s13238-020-00710-0"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Yang K., Homa F., Baines J.D. Putative terminase subunits of herpes simplex virus 1 form a complex in the cytoplasm and interact with portal protein in the nucleus. J. Virol. 2007; 81(12): 6419\u201333. https:\/\/doi.org\/10.1128\/JVI.00047-07","DOI":"10.1128\/JVI.00047-07"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ligat G., Cazal R., Hantz S., Alain S. The human cytomegalovirus terminase complex as an antiviral target: a close-up view. FEMS Microbiol. Rev. 2018; 42(2): 137\u201345. https:\/\/doi.org\/10.1093\/femsre\/fuy004","DOI":"10.1093\/femsre\/fuy004"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Wang Y., Mao L., Kankanala J., Wang Z., Geraghty R.J. Inhibition of human cytomegalovirus pUL89 terminase subunit blocks virus replication and genome cleavage. J. Virol. 2017; 91(3): e02152\u201316. https:\/\/doi.org\/10.1128\/JVI.02152-16","DOI":"10.1128\/JVI.02152-16"},{"key":"ref21","unstructured":"Plunkett W., Cohen S.S. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells. Cancer Res. 1975; 35(6): 1547\u201354."},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Xiong X., Smith J.L., Chen M.S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother.1997; 41(3): 594\u20139. https:\/\/doi.org\/10.1128\/AAC.41.3.594","DOI":"10.1128\/AAC.41.3.594"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Lycke J., Malmestr\u00f6m C., St\u00e5hle L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob. Agents Chemother. 2003; 47(8): 2438\u201341. https:\/\/doi.org\/10.1128\/AAC.47.8.2438-2441.2003","DOI":"10.1128\/AAC.47.8.2438-2441.2003"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Pue M.A., Benet L.Z. Pharmacokinetics of famciclovir in man. Antivir. Chem. Chemother. 1993; 4(1): 47\u201355. https:\/\/doi.org\/10.1177\/09563202930040S602","DOI":"10.1177\/09563202930040S602"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Andrei G., Snoeck R., De Clercq E., Esnouf R., Fiten P., Opdenakker G. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J. Gen. Virol. 2000; 81(3): 639\u201348. https:\/\/doi.org\/10.1099\/0022-1317-81-3-639","DOI":"10.1099\/0022-1317-81-3-639"},{"key":"ref26","unstructured":"FOSCARNET SODIUM \u2013 foscarnet sodium injection, solution. Hospira, Inc. Available at: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=4451"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Zuo J., Meng T., Wang Y., Tang W. A review of the antiviral activities of glycyrrhizic acid, glycyrrhetinic acid and glycyrrhetinic acid monoglucuronide. Pharmaceuticals (Basel). 2023; 16(5): 641. https:\/\/doi.org\/10.3390\/ph16050641","DOI":"10.3390\/ph16050641"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Salazar G., Urb\u00e1n-Morl\u00e1n Z., Mendoza-Elvira S., Quintanar-Guerrero D., Mendoza S. Broad antiviral spectrum of glycyrrhizic acid for human and veterinary medicine: reality or fiction? Intervirology. 2023; 66(1): 41\u201353. https:\/\/doi.org\/10.1159\/000528198","DOI":"10.1159\/000528198"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Danastas K., Miranda-Saksena M., Cunningham A.L. Herpes simplex virus type 1 interactions with the interferon system. Int. J. Mol. Sci. 2020; 21(14): 5150. https:\/\/doi.org\/10.3390\/ijms21145150","DOI":"10.3390\/ijms21145150"},{"key":"ref30","unstructured":"Clinical guidelines \u00abHerpes simplex (HS) in adults\u00bb; 2022. Available at: https:\/\/edu.nmrc.ru\/wp-content\/uploads\/2022\/04\/kr_prostoy_gerppes-1.pdf"}],"container-title":["Problems of Virology"],"original-title":[],"link":[{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/viewFile\/16792\/1075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/viewFile\/16792\/1075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:36:37Z","timestamp":1775226997000},"score":1,"resource":{"primary":{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/view\/16792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,23]]}},"URL":"https:\/\/doi.org\/10.36233\/0507-4088-336","relation":{},"ISSN":["2411-2097","0507-4088"],"issn-type":[{"value":"2411-2097","type":"electronic"},{"value":"0507-4088","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}